The PARADIGM-HF study evaluated the efficacy of LCZ696, a concomitant inhibitor of<unk>  and<unk><unk> , on the rate of mortality due to cardiovascular causes and hospitalization.  Compared to enalapril,<unk><unk><unk>  inhibitor significantly reduced the rate of hospitalization by 21% and decreased the rate of cardiovascular and hospitalization-related deaths from 26.5% to 21.8%.  The administration of<unk><unk><unk>  inhibitor reduced chronic heart failure symptoms and the associated limitation of physical activity.
Congestive heart failure angiotensin receptor-neprilysin inhibitor
Congestive heart failure aldosterone antagonists
Congestive heart failure Sodium-glucose co-transporter 2 inhibitors
Congestive heart failure calcium channel blockers
Unstable angina / non ST elevation myocardial infarction inhibitors of RAS
Congestive heart failure vasodilators
Congestive heart failure Pharmacological treatments for patients with heart failure with reduced ejection fraction
Congestive heart failure diuretics